 Kenneth Knecht
Concepts (180)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 23 | 2024 | 366 | 3.720 |
Why?
| | Graft Rejection | 12 | 2024 | 173 | 1.870 |
Why?
| | Heart Failure | 5 | 2020 | 531 | 0.890 |
Why?
| | Cardiomyopathy, Dilated | 3 | 2023 | 39 | 0.780 |
Why?
| | Child | 29 | 2024 | 6931 | 0.710 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 53 | 0.690 |
Why?
| | Tissue Donors | 7 | 2024 | 121 | 0.680 |
Why?
| | Child, Preschool | 19 | 2024 | 3953 | 0.650 |
Why?
| | Cerebrovascular Circulation | 2 | 2010 | 132 | 0.640 |
Why?
| | Down Syndrome | 2 | 2022 | 90 | 0.640 |
Why?
| | Adolescent | 23 | 2024 | 6453 | 0.610 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2016 | 31 | 0.520 |
Why?
| | Muscular Dystrophy, Duchenne | 3 | 2022 | 24 | 0.510 |
Why?
| | Athletes | 1 | 2016 | 98 | 0.510 |
Why?
| | Myocarditis | 3 | 2021 | 46 | 0.460 |
Why?
| | Telangiectasia, Hereditary Hemorrhagic | 1 | 2013 | 6 | 0.440 |
Why?
| | Renal Insufficiency | 1 | 2014 | 109 | 0.440 |
Why?
| | Heart-Assist Devices | 5 | 2021 | 156 | 0.430 |
Why?
| | Carbon Monoxide | 2 | 2010 | 40 | 0.430 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2015 | 180 | 0.430 |
Why?
| | Cardiomyopathies | 3 | 2021 | 119 | 0.420 |
Why?
| | Receptors, Cell Surface | 1 | 2013 | 117 | 0.410 |
Why?
| | Humans | 39 | 2024 | 50419 | 0.410 |
Why?
| | Heart Defects, Congenital | 4 | 2022 | 603 | 0.400 |
Why?
| | Antigens, CD | 1 | 2013 | 221 | 0.400 |
Why?
| | Central Nervous System Stimulants | 1 | 2014 | 209 | 0.390 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 28 | 0.380 |
Why?
| | Atrial Septum | 1 | 2011 | 4 | 0.380 |
Why?
| | Heart Rupture | 1 | 2011 | 10 | 0.380 |
Why?
| | Male | 25 | 2024 | 25866 | 0.370 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2011 | 46 | 0.370 |
Why?
| | Infant | 13 | 2024 | 3648 | 0.360 |
Why?
| | Peptide Fragments | 1 | 2012 | 208 | 0.360 |
Why?
| | Pia Mater | 1 | 2010 | 4 | 0.340 |
Why?
| | Vasoconstriction | 1 | 2010 | 56 | 0.340 |
Why?
| | Donor Selection | 2 | 2020 | 18 | 0.330 |
Why?
| | Kidney | 1 | 2014 | 690 | 0.330 |
Why?
| | Vasoconstrictor Agents | 1 | 2010 | 83 | 0.330 |
Why?
| | Retrospective Studies | 16 | 2024 | 6274 | 0.330 |
Why?
| | Angiotensin II | 1 | 2010 | 159 | 0.320 |
Why?
| | Vasodilation | 1 | 2010 | 98 | 0.320 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 464 | 0.320 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 997 | 0.320 |
Why?
| | Reoperation | 1 | 2011 | 461 | 0.320 |
Why?
| | Auscultation | 1 | 2009 | 9 | 0.310 |
Why?
| | Blood Pressure Determination | 1 | 2009 | 39 | 0.310 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1020 | 0.300 |
Why?
| | Cardiac Surgical Procedures | 1 | 2011 | 314 | 0.290 |
Why?
| | Cardiac Catheterization | 2 | 2024 | 223 | 0.290 |
Why?
| | Echocardiography, Transesophageal | 2 | 2023 | 60 | 0.290 |
Why?
| | Female | 22 | 2024 | 27053 | 0.290 |
Why?
| | Waiting Lists | 4 | 2022 | 59 | 0.270 |
Why?
| | Infant, Newborn | 6 | 2020 | 2752 | 0.260 |
Why?
| | Ventricular Function, Left | 2 | 2019 | 169 | 0.250 |
Why?
| | Anesthesia, General | 1 | 2024 | 99 | 0.220 |
Why?
| | Fontan Procedure | 2 | 2021 | 70 | 0.220 |
Why?
| | Isoantibodies | 2 | 2013 | 29 | 0.200 |
Why?
| | HLA Antigens | 2 | 2013 | 52 | 0.200 |
Why?
| | Dystrophin | 1 | 2022 | 6 | 0.190 |
Why?
| | Odds Ratio | 2 | 2014 | 550 | 0.190 |
Why?
| | Graft Survival | 3 | 2020 | 160 | 0.190 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 32 | 0.180 |
Why?
| | Arterioles | 2 | 2010 | 34 | 0.170 |
Why?
| | Risk Factors | 8 | 2021 | 3712 | 0.170 |
Why?
| | Prospective Studies | 4 | 2024 | 2378 | 0.160 |
Why?
| | Models, Statistical | 1 | 2021 | 224 | 0.160 |
Why?
| | Animals, Newborn | 2 | 2010 | 361 | 0.160 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 50 | 0.160 |
Why?
| | Diagnosis, Differential | 2 | 2013 | 1029 | 0.160 |
Why?
| | Myocardium | 2 | 2019 | 443 | 0.160 |
Why?
| | Cardiopulmonary Resuscitation | 2 | 2020 | 138 | 0.160 |
Why?
| | Swine | 2 | 2010 | 408 | 0.160 |
Why?
| | Consensus | 1 | 2020 | 159 | 0.150 |
Why?
| | Defibrillators, Implantable | 1 | 2020 | 66 | 0.150 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2020 | 107 | 0.150 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2019 | 294 | 0.150 |
Why?
| | Treatment Outcome | 9 | 2022 | 5265 | 0.150 |
Why?
| | Severity of Illness Index | 1 | 2021 | 976 | 0.140 |
Why?
| | Adult | 9 | 2024 | 13561 | 0.140 |
Why?
| | Ventricular Dysfunction | 1 | 2017 | 10 | 0.140 |
Why?
| | Defibrillators | 1 | 2016 | 7 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2019 | 2231 | 0.130 |
Why?
| | Electric Countershock | 1 | 2016 | 30 | 0.130 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2016 | 27 | 0.130 |
Why?
| | Hospitalization | 1 | 2021 | 677 | 0.130 |
Why?
| | Age Factors | 3 | 2021 | 1118 | 0.120 |
Why?
| | Risk Assessment | 1 | 2020 | 1268 | 0.120 |
Why?
| | Age of Onset | 1 | 2015 | 109 | 0.120 |
Why?
| | Kidney Function Tests | 1 | 2014 | 52 | 0.120 |
Why?
| | Body Surface Area | 1 | 2014 | 26 | 0.120 |
Why?
| | Steroids | 1 | 2015 | 57 | 0.120 |
Why?
| | Creatinine | 1 | 2014 | 142 | 0.110 |
Why?
| | Glomerular Filtration Rate | 1 | 2014 | 119 | 0.110 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 138 | 0.110 |
Why?
| | Tachycardia | 1 | 2014 | 27 | 0.110 |
Why?
| | Methylphenidate | 1 | 2014 | 76 | 0.110 |
Why?
| | Regression Analysis | 1 | 2014 | 376 | 0.110 |
Why?
| | Polysomnography | 1 | 2013 | 71 | 0.110 |
Why?
| | Cardiovascular Abnormalities | 1 | 2013 | 26 | 0.110 |
Why?
| | Echocardiography | 3 | 2022 | 398 | 0.110 |
Why?
| | Vena Cava, Inferior | 1 | 2013 | 78 | 0.100 |
Why?
| | Time Factors | 3 | 2021 | 2933 | 0.100 |
Why?
| | Young Adult | 4 | 2020 | 4075 | 0.100 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 227 | 0.100 |
Why?
| | Embolization, Therapeutic | 1 | 2013 | 87 | 0.100 |
Why?
| | Registries | 1 | 2015 | 565 | 0.100 |
Why?
| | Heart Ventricles | 1 | 2014 | 266 | 0.090 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2011 | 22 | 0.090 |
Why?
| | Suture Techniques | 1 | 2011 | 61 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2012 | 104 | 0.090 |
Why?
| | Boronic Acids | 1 | 2012 | 182 | 0.090 |
Why?
| | Pyrazines | 1 | 2012 | 187 | 0.090 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2010 | 4 | 0.090 |
Why?
| | Prostaglandins | 1 | 2010 | 18 | 0.090 |
Why?
| | Nitric Acid | 1 | 2010 | 5 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 507 | 0.090 |
Why?
| | Nitroprusside | 1 | 2010 | 11 | 0.090 |
Why?
| | Feedback, Physiological | 1 | 2010 | 12 | 0.090 |
Why?
| | Potassium Channels, Calcium-Activated | 1 | 2010 | 5 | 0.090 |
Why?
| | Isoproterenol | 1 | 2010 | 56 | 0.080 |
Why?
| | Nitric Oxide Synthase | 1 | 2010 | 69 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2010 | 96 | 0.080 |
Why?
| | Logistic Models | 1 | 2012 | 901 | 0.080 |
Why?
| | Cardiotonic Agents | 2 | 2020 | 82 | 0.080 |
Why?
| | Endothelium, Vascular | 1 | 2010 | 244 | 0.080 |
Why?
| | Cause of Death | 2 | 2020 | 150 | 0.080 |
Why?
| | Diastole | 1 | 2009 | 70 | 0.080 |
Why?
| | Biopsy | 2 | 2022 | 588 | 0.080 |
Why?
| | Systole | 1 | 2009 | 72 | 0.080 |
Why?
| | Arginine | 1 | 2010 | 185 | 0.080 |
Why?
| | Reference Values | 1 | 2009 | 302 | 0.070 |
Why?
| | Nitric Oxide | 1 | 2010 | 253 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 1163 | 0.070 |
Why?
| | Electrocardiography | 2 | 2020 | 266 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 1369 | 0.070 |
Why?
| | Survival Rate | 2 | 2021 | 906 | 0.060 |
Why?
| | Ipratropium | 1 | 2005 | 1 | 0.060 |
Why?
| | Animals | 2 | 2010 | 13063 | 0.060 |
Why?
| | Albuterol | 1 | 2005 | 57 | 0.060 |
Why?
| | Bronchodilator Agents | 1 | 2005 | 76 | 0.060 |
Why?
| | Cohort Studies | 2 | 2022 | 1451 | 0.050 |
Why?
| | Databases, Factual | 2 | 2016 | 676 | 0.050 |
Why?
| | Aorta | 1 | 2023 | 159 | 0.050 |
Why?
| | Incidence | 2 | 2015 | 1027 | 0.050 |
Why?
| | Prognosis | 2 | 2019 | 1974 | 0.050 |
Why?
| | Antibodies | 1 | 2022 | 151 | 0.050 |
Why?
| | Ventricular Function, Right | 1 | 2022 | 39 | 0.050 |
Why?
| | Asthma | 1 | 2005 | 303 | 0.050 |
Why?
| | Protein-Losing Enteropathies | 1 | 2021 | 4 | 0.050 |
Why?
| | Treatment Failure | 1 | 2021 | 120 | 0.050 |
Why?
| | Warm Ischemia | 1 | 2020 | 3 | 0.040 |
Why?
| | Troponin | 1 | 2020 | 12 | 0.040 |
Why?
| | Cold Ischemia | 1 | 2020 | 10 | 0.040 |
Why?
| | Hemodynamics | 1 | 2021 | 263 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 924 | 0.040 |
Why?
| | Troponin I | 1 | 2019 | 18 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 223 | 0.040 |
Why?
| | Chest Pain | 1 | 2019 | 55 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2021 | 732 | 0.040 |
Why?
| | Disease Progression | 1 | 2022 | 825 | 0.040 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2019 | 80 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2021 | 1085 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2019 | 298 | 0.030 |
Why?
| | Mutation | 1 | 2022 | 1275 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 658 | 0.030 |
Why?
| | Propensity Score | 1 | 2015 | 136 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 373 | 0.030 |
Why?
| | Azygos Vein | 1 | 2013 | 11 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 462 | 0.030 |
Why?
| | Coronary Circulation | 1 | 2013 | 59 | 0.030 |
Why?
| | Aged | 1 | 2019 | 9738 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2005 | 87 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 128 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2005 | 113 | 0.010 |
Why?
| | United States | 1 | 2015 | 5005 | 0.010 |
Why?
| | Emergency Medicine | 1 | 2005 | 52 | 0.010 |
Why?
| | Nebulizers and Vaporizers | 1 | 2005 | 58 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 12579 | 0.010 |
Why?
| | Acute Disease | 1 | 2005 | 374 | 0.010 |
Why?
| | Pediatrics | 1 | 2005 | 285 | 0.010 |
Why?
|
|
Knecht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|